These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 1792994

  • 1. [Orchiectomy and buserelin in combination with flutamide: comparative results in metastatic prostatic carcinoma].
    Mora MJ, Extramiana J, Paniagua P, González P, Mañas A, Pérez MJ, Navarro J, Arrizabalaga M.
    Actas Urol Esp; 1991; 15(6):548-52. PubMed ID: 1792994
    [Abstract] [Full Text] [Related]

  • 2. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma.
    Boccon-Gibod L, Fournier G, Bottet P, Marechal JM, Guiter J, Rischman P, Hubert J, Soret JY, Mangin P, Mallo C, Fraysse CE.
    Eur Urol; 1997; 32(4):391-5; discussion 395-6. PubMed ID: 9412794
    [Abstract] [Full Text] [Related]

  • 3. Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients with advanced prostate cancer.
    Labrie F, Dupont A, Giguère M, Borsanyi JP, Lacourciere Y, Bélanger A, Lachance R, Emond J, Monfette G.
    Prog Clin Biol Res; 1988; 260():41-62. PubMed ID: 3283766
    [Abstract] [Full Text] [Related]

  • 4. Results of a Dutch trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer and results of EORTC studies in prostatic cancer.
    Debruyne FM.
    Am J Clin Oncol; 1988; 11 Suppl 1():S33-5. PubMed ID: 2968760
    [Abstract] [Full Text] [Related]

  • 5. The treatment of advanced prostatic carcinoma with total androgenic blockade using bilateral orchidectomy and flutamide: experience at the National Cancer Institute in Mexico.
    Mendoza-Valdés A, Ocampo-del-Carpio O, De-la-Garza J.
    Semin Oncol; 1991 Oct; 18(5 Suppl 6):19-20. PubMed ID: 1948118
    [Abstract] [Full Text] [Related]

  • 6. Combined androgen blockade in the management of advanced prostate cancer: a sensible or ostensible approach.
    Ansari MS, Gupta NP, Hemal AK, Dogra PN, Seth A.
    Int J Urol; 2004 Dec; 11(12):1092-6. PubMed ID: 15663681
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Does total androgen suppression in advanced prostatic cancer induce a greater number of complete remissions? A phase II trial].
    Germà Lluch JR, Izquierdo Delso MA, Seguí Palmer MA, Villavicencio H, Ojeda González B, de Andrés Basauri L, Pallarés Curto C.
    Actas Urol Esp; 1991 Dec; 15(1):34-8. PubMed ID: 1905458
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Epirubicin plus flutamide and orchidectomy in previously untreated advanced prostatic cancer.
    Pummer K.
    Semin Oncol; 1991 Oct; 18(5 Suppl 6):26-8. PubMed ID: 1948120
    [Abstract] [Full Text] [Related]

  • 15. [Final results of complete hormone blockade versus monotherapy in prostatic metastatic cancer. PSA implications].
    Morote J, Vallejo C, Lorente JA, Encabo G, López Pacios MA, de Torres JA, Soler Roselló A.
    Actas Urol Esp; 1995 Sep; 19(8):604-10. PubMed ID: 8669327
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of buserelin in advanced prostate cancer and comparison with historical controls.
    Soloway MS.
    Am J Clin Oncol; 1988 Sep; 11 Suppl 1():S29-32. PubMed ID: 3133944
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.